216 results
8-K
EX-99.1
TXMD
TherapeuticsMD Inc
29 Oct 18
Regulation FD Disclosure
6:04am
to menopause in women with a uterus.
“The approval of BIJUVA represents an important and new opportunity for menopausal women suffering from moderate … to severe vasomotor symptoms. Menopausal women and their healthcare providers have been seeking bio-identical combination therapies for many years without
8-K
EX-99.1
TXMD
TherapeuticsMD Inc
13 Jan 21
Entry into a Material Definitive Agreement
8:50am
by this PBM for more than 50,000 women – Continue to find new ways to engage doctors virtually while traditional access is limited – Marketing efforts … company filings; (2) Internal research findings ▪ 60% of women in this category know the birth control method they want before seeing their Healthcare
8-K
EX-99.1
TXMD
TherapeuticsMD Inc
30 May 18
Regulation FD Disclosure
6:01am
. It dissolves completely without mess or additional clean-up, and can be used anytime of day. It allows women the freedom to immediately return … that women want, based on the concepts of medical need, efficacy, safety, simplicity, and affordability. IMVEXXY will be offered at a price in parity
8-K
EX-99.2
TXMD
TherapeuticsMD Inc
13 Aug 18
TherapeuticsMDAnnounces FDA Approval of ANNOVERA ™(Segesterone Acetate/Ethinyl Estradiol Vaginal System) for Birth Control
6:01am
pivotal Phase 3 clinical trials with 2,308 women – Efficacy and safety consistent with other birth control pills, patches and hormonal rings ▪ … CHCs carry the boxed warning about cigarette smoking and serious cardiovascular events, particularly for women over age 35 – The risk profile
8-K
EX-99.2
TXMD
TherapeuticsMD Inc
17 Apr 19
TherapeuticsMD Signs Binding Commitment Letter for $300 Million Non-Dilutive Term Loan Financing Facility with TPG Sixth Street Partners
4:08pm
in women with a uterus. BIJUVA offers a proven balance of bio-identical estradiol to reduce moderate to severe hot flashes combined with bio-identical … and the combined use of separate estrogen and progesterone products.
“We are excited to offer women, healthcare providers and pharmacists an answer to their desire
8-K
EX-99.1
rn4vz
13 Aug 18
TherapeuticsMDAnnounces FDA Approval of ANNOVERA ™(Segesterone Acetate/Ethinyl Estradiol Vaginal System) for Birth Control
6:01am
8-K
EX-99.1
uf27o
13 Nov 18
Regulation FD Disclosure
6:49am
8-K
EX-99.1
egwcnm
1 Oct 19
1 Investor Presentation October 2019 Building a Premier Women’s Health Portfolio
7:01am
8-K
EX-99.1
tztvkj
8 Jan 19
Regulation FD Disclosure
7:01am
8-K
EX-99.1
w8nab4ncqb asjpz
18 Nov 14
Regulation FD Disclosure
12:00am
8-K
EX-99.1
z2hq9kwow6ir
27 Nov 18
Regulation FD Disclosure
6:49am
8-K
EX-99.1
x27ui96
7 Nov 18
TherapeuticsMD Announces Third Quarter 2018 Financial Results
4:08pm
8-K
EX-99.1
r7dzxlf
14 Jun 13
Regulation FD Disclosure
12:00am
8-K
EX-99.1
dwd21ybsip 50ty
16 Sep 19
1 Investor Presentation September 2019 Building a Premier Women’s Health Portfolio
6:46am
8-K
EX-99.2
aablfm2jy7a5pfhfgvu
9 Nov 20
TherapeuticsMD® Announces Third Quarter 2020 Financial Results
6:55am
8-K
EX-99.1
3qttlklr
24 Sep 18
Regulation FD Disclosure
7:00am
8-K
EX-99.1
foquv 50v7
10 Jun 19
Regulation FD Disclosure
2:28pm
8-K
EX-99.1
9qs9dgk 4jn
12 Jan 15
Regulation FD Disclosure
12:00am
8-K
EX-99.1
3z3rd7lzj
9 Jul 19
Regulation FD Disclosure
6:57am
8-K
EX-99.1
ohigwv81hapmpw
7 Jun 19
TherapeuticsMD and Theramex Enter into Exclusive License and Supply Agreement to Commercialize BIJUVA™ and IMVEXXY® Outside the United States
7:15am